SYF6565e015c68f4bff8c421eba07c9e9e7Registry ID: 2023-506035-15-00|UnknownPhase 1Results
Loading search results
interventional
N/A
1 country
1
To evaluate the relative bioavailability of the test formulation of apixaban compared to the commercial formulations taken as reference and to demonstrate their bioequivalence according to health authorities’ criteria.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
June 15, 2023
Actual (reported)AUC0-t and Cmax of apixaban
AUC0-∞, Tmax and residual area of apixaban
These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.
Formulated product
Eliquis 5 mg film-coated tablets
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
FILM-COATED TABLET
View registry recordFormulated product
Apixaban 5 mg Cápsula dura
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
CAPSULE, HARD
View registry recordThe registry names these ingredients. The formulation’s exact chemical form has not been confirmed.
Eliquis 5 mg film-coated tablets
Named ingredient: apixaban
View registry recordApixaban 5 mg Cápsula dura
Named ingredient: apixaban
View registry recordHospital Universitario De La Princesa
Madrid, 28006, Spain
Carmen Morillo Alonso
First Submitted
June 15, 2023
Download the complete CTIS (EMA) record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: European Medicines Agency (EMA), Clinical Trials Information System (CTIS). Original record and public documents are available on CTIS.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved:
Contact the study team to confirm eligibility.